- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
I
Objective
MTN-036/IPM 047 is a Phase 1, randomized, three-arm, open label trial. The study will assess the safety and pharmacokinetics (PK) of three silicone elastomer intravaginal rings (VRs) containing either 25 mg or 200 mg of the active ingredient dapivirine (DPV) formulated using either polymer 4320 or 4870.
*The study is closed to follow up*
Last updated May 9, 2021
Prevention Option(s)
Microbicides
Study Design
Randomized
Open label
Arms and Assigned Interventions
Description
Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks.
Mode of Delivery
Ring
Products
Dapivirine Ring
ARMs
Experimental
Description
Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks
Mode of Delivery
Ring
Products
Dapivirine Ring
ARMs
Experimental
Description
Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks.
Mode of Delivery
Ring
Products
Dapivirine Ring
ARMs
Experimental
Official Code
Trial Sponsors
NIAID, NICHD, NIMH, NIH, IPM
December 2017
January 2019
Date of Enrollment Completion
October 23, 2018
Enrollment
49
18
Years
45
Years
Population
Women
Sites
Alabama Microbicide CRS
Birmingham, Alabama
United States of America
Bridge HIV CRS
San Francisco, California
United States of America